Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...

Lexicon (LXRX) announced The Lancet Diabetes & Endocrinology has published a research paper analyzing the ability of sotagliflozin, a dual ...

The deaths are also partly the result of medical successes: People are living longer, and more people are surviving heart ...

A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...

A new study finds SGLT2 inhibitors like Jardiance and GLP-1 drugs like Ozempic provide different benefits depending on the ...

Opens in a new tab or window SGLT2 inhibitors were more cardioprotective ... Data on additional outcomes like end-stage kidney disease, heart failure, and medication-related harms weren't assessed.

They added that “it seems very likely that SGLT2 inhibitors will also result in a substantial reduction in recurrent stone events in patients with pure [calcium oxalate] stones.” Despite the concern ...

Use of proton pump inhibitors appears to increase the risk ... apparent even after controlling for diabetes, hypertension, heart failure, and use of other medications. According to Dr Rhee ...

In the 21st century, the worldwide obesity epidemic means that diabetes, CKD, and heart disease together now contribute to mortality and functional decline more than diarrheal illness. SGLT2 ...

It’s hard to do daily management in a small enclosure, because often they will die from stress.” When veterinarians and zoologists do work with ... room for you in my heart as well.